

Policy Name:	Naglazyme (galsulfase)	Policy #:	2479P
---------------------	-------------------------------	------------------	--------------

Purpose of the Policy

The purpose of this policy is to establish the criteria for coverage of Naglazyme (galsulfase).

Statement of the Policy

Health Alliance Medical Plans will approve the use of Naglazyme (galsulfase) under the Specialty Medical benefit when the following criteria have been met.

Criteria

1. Coverage Criteria for the Treatment of Maroteaux-Lamy syndrome (MPS type VI)

- 1.1 Diagnosis of Mucopolysaccharidosis (MPS type VI) with testing that shows evidence of gene mutation
- 1.2 Prescribed by a geneticist (gene specialist)

2. Approval Period

- 2.1 Initial: 12 months
- 2.2 Reauthorization: 12 months with documented clinical benefit from therapy

CPT Codes

--	--

HCPCS Codes

J1458	Injection, galsulfase, 1mg (Naglazyme)
-------	--

References

1. Naglazyme (galsulfase) [prescribing information]. Novato, CA: BioMarin Pharmaceutical Inc.; July 2024.
2. Brunelli MJ, Atallah AN, da Silva EM. Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI. *Cochrane Database Syst Rev* 2016; 3:CD009806.
3. Giugliani R, Harmatz P, and Wraith JE, "Management Guidelines for Mucopolysaccharidosis VI," *Pediatrics*, 2007, 120(2):405-18.
4. Giugliani R, Lampe C, Guffon N, et al. Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)--10-year follow-up of patients who previously participated in an MPS VI Survey Study. *Am J Med Genet A*. 2014;164A(8):1953-1964.
5. Harmatz P, Giugliani R, Schwartz I, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. *J Pediatr* 2006; 148:533.

6. Harmatz PR, Garcia P, Guffon N, et al. Galsulfase (Naglazyme®) therapy in infants with mucopolysaccharidosis VI. J Inherit Metab Dis. 2014;37(2):277-287.

Created Date: 04/06/16

Effective Date: 04/06/16

Posted to Website: 01/01/22

Revision Date: 10/02/24

DISCLAIMER

This Medical Policy has been developed as a guide for determining medical necessity. The process of medical necessity review also entails review of the most recent literature and physician review. Medical Policy is not intended to dictate to providers how to practice medicine. Providers are expected to exercise their medical judgment in providing the most appropriate care. Health Alliance encourages input from providers when developing and implementing medical policies. Benefit determinations are based on applicable contract language in the member's Policy/ Subscription Certificate/ Summary Plan Description. This Medical Policy does not guarantee coverage. There may be a delay between the revision of this policy and the posting on the web. Please contact the Health Alliance Customer Service Department at 1-800-851-3379 for verification of coverage.